Powered by lexis nexis

Novus Therapeutics Reports Second Quarter 2017 Results

Aug 09, 2017 - PR Newswire

 Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (ENT), today reported results for the second quarter 2017. 

For the three months ended June 30, 2017, the Novus reported a net loss of $6.7 million or $1.32 per share.  This compares to a net loss of $1.0 million or $2.25 per share for the same period in the prior year.  For the six months ended June 30, 2017, N...